HIF1α regulated expression of XPA contributes to cisplatin resistance in lung cancer

Carcinogenesis

Volumn 33, Issue 6, 2012, Pages 1187-1192

  Liu, Yanbin ^a   Bernauer, Amanda M ^a   Yingling, Christin M ^a   Belinsky, Steven A ^a  

^a LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; COBALT CHLORIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; SMALL INTERFERING RNA; XERODERMA PIGMENTOSUM GROUP A PROTEIN;

ANIMAL CELL; ARTICLE; BRONCHUS MUCOSA; CANCER CELL CULTURE; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DNA RESPONSIVE ELEMENT; DNA TEMPLATE; DRUG SENSITIVITY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; TRANSCRIPTION REGULATION;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; COBALT; DNA REPAIR; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LUNG NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC; XERODERMA PIGMENTOSUM GROUP A PROTEIN;

EID: 84864294365     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs142     Document Type: Article

References (43)

1. Jackson,S.P. et al. (2009) The DNA-damage response in human biology and disease. Nature, 461, 1071-1078.
2. Helleday,T. et al. (2008) DNA repair pathways as targets for cancer therapy. Nat. Rev. Cancer, 8, 193-204.
3. Hanawalt, P.C. (2002) Subpathways of nucleotide excision repair and their regulation. Oncogene, 21, 8949-8956.
4. Morita,E.H. et al. (1996) Implications of the zinc-finger motif found in the DNA-binding domain of the human XPA protein. Genes Cells, 1, 437-442.
5. Krasikova,Y.S. et al. (2008) Interaction of nucleotide excision repair factors XPC-HR23B, XPA, and RPA with damaged DNA. Biochemistry (Mosc.), 73, 886-896.
6. Tsodikov,O.V. et al. (2007) Structural basis for the recruitment of ERCC1-XPF to nucleotide excision repair complexes by XPA. EMBO J., 14, 4768-4776.
7. Nocentini,S. et al. (1997) DNA damage recognition by XPA protein promotes efficient recruitment of transcription factor II H. J. Biol. Chem., 272, 22991-22994.
8. Li,L. et al. (1994) Specific association between the human DNA repair proteins XPA and ERCC1. Proc. Natl Acad. Sci. USA, 91, 5012-5016.
9. Tanaka,K. et al. (2001) UV-induced skin carcinogenesis in xeroderma pigmentosum group A (XPA) gene-knockout mice with nucleotide excision repair-deficiency. Mutat. Res., 477, 31-40.
10. Sleijfer,D.T. et al. (1985) Cisplatin: a review of clinical applications and renal toxicity. Pharm. Weekbl. Sci., 7, 237-244.
11. Johnes,J. et al. (1991) Gene-specific formation and repair of cisplatin intrastrand adducts and interstrand cross-links in Chinese hamster ovary. J. Biol. Chem., 266, 7107-7107.
12. Sancar, A. (1995) Excision repair in mammalian cells. J. Biol. Chem., 270, 15915-15918.
13. Wu,X. et al. (2003) Sensitization to the cytotoxicity of cisplatin by transfection with nucleotide excision repair gene xeroderma pigmentosun group A antisense RNA in human lung adenocarcinoma cells. Clin. Cancer Res., 9, 5874-5879.
14. Cummings, M. et al. (2006) XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin C in prostate cancer cells: role of ERCC1 in homologous recombination repair. Biochem. Pharmacol., 72, 166-175.
15. Weaver,D.A. et al. (2005) ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. Mol. Cancer, 4, 18.
16. Dhimizu,J. et al. (2008) mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines. Respirology, 13, 510-517.
17. Chen,J. et al. (2010) Resistance to platinum-based chemotherapy in lung cancer cell lines. Cancer Chemother. Pharmacol., 66, 1103-1111.
18. Saviozzi,S. et al. (2009) Non-small cell lung cancer exhibits transcript overexpression of genes associated with homologous recombination and DNA replication pathways. Cancer Res., 69, 3390-3396.
19. Friboulet,L. et al. (2011) Molecular characteristics of ERCC1-negative versus ERCC1-positive tumors in resected NSCLC. Clin. Cancer Res., 17, 5562-5572.
20. Chen,S. et al. (2010) The platinum-based treatments for advanced nonsmall cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis. Lung Cancer, 70, 63-70.
21. Lord,R.V. et al. (2002) Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin. Cancer Res., 8, 2286-2291.
22. Rosell,R. et al. (2004) Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin. Cancer Res., 10, 1318-1325.
23. Reynolds,C. et al. (2009) Randomized phase III trial of gemcitabinebased chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J. Clin. Oncol., 27, 5808-5815.
24. Tessema,M. et al. (2009) Concomitant promoter Methylation of multiple genes in lung adenocarcinomas from current, former and never smokers. Carcinogenesis, 30, 1132-1138.
25. Belinsky,S.A. et al. (2002) Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res., 62, 2370-2377.
26. Ramirez,R.D. et al. (2004) Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res., 64, 9027-9034.
27. Livak,K.J. et al. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)). Methods, 25, 402-408.
28. Quandt,K. et al. (1995) MatInd and matInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res., 23, 4878-4884.
29. Kimura,H. et al. (2000) Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: control of hypoxia-inducible factor-1 activity by nitric oxide. Blood, 95, 189-197.
30. Kopacek,J. et al. (2005)MAPK pathway contributes to density- and hypoxiainduced expression of the tumor-associated carbonic anhydrase IX. Biochim. Biophys. Acta, 1729, 41-49.
31. Tessema,M. et al. (2011) SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topotecan via induction of ISG15. Oncogene, doi:10.1038/onc.2011.577
32. Leng,S. et al. (2011) The A/G allele of Rs16906252 predicts for MGMT methylation and is selectively silenced in premalignant lesions from smokers and in lung adenocarcinoma. Clin. Cancer Res., 17, 2014-2023.
33. Janga,S.C. et al. (2011) MicroRNAs as post-transcriptional machines and their interplay with cellular networks. Adv. Exp. Med. Biol., 722, 59-74.
34. Pouyssegur,J. et al. (2006) Hypoxia signaling in cancer and approaches to enforcer tumour regression. Nature, 441, 437-443.
35. Harris, A.L. (2002) Hypoxia-a key regulatory factor in tumour growth. Nat. Rev. Cancer, 2, 38-47.
36. Pugh,C.W. et al. (2003) Regulation of angiogenesis by hypoxia: role of the HIF system. Nat. Med., 9, 677-684.
37. Nakayama, K. (2009) Cellular signal transduction of the hypoxia response. J. Biochem., 146, 757-765.
38. Rey,S. et al. (2010) Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodeling. Cardiovasc. Res., 86, 236-242.
39. Huang,L.E. et al. (1996) Activation of hypoxia-inducible transcription factor depends primarily upon redoxsensitive stabilizaton of its α subunit. J. Biol. Chem., 271, 32253-32259.
40. Wang,F.S. et al. (2004) Ras inductiono f superoxide activates ERKdependent angiogenic transcription factor HIF-1alpha and VEGF-A expression in shock wave-stimulated osteoblasts. J. Biol. Chem., 279, 10331-10337.
41. Su,W. et al. (2011) Noscapine sensitizes chemoresistant ovarian cancer cells to cisplatin through inhibition of HIF-1α. Cancer Lett., 305, 94-99.
42. Narita,T. et al. (2009) Identification of a novel small molecule HIF-1alpha translation inhibitor. Clin. Cancer Res., 25, 6128-6136.
43. Lee,G.-W. et al. (2012) Hypoxia-inducible factor-1α and excision repair cross-complementing 1 in patients with small cell lung cancer who received front-line platinum-based chemotherapy. A retrospective study. J. Thorac. Oncol., 7, 528-534.